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Abstract
This study examined the effects of the Dietary Approaches to Stop Hypertension (DASH) diet on
insulin sensitivity and lipids. In a randomized control trial, 144 overweight (body mass index 25–
40) men (N= 47) and women (N= 97) with high blood pressure (130–159/85–99 mm Hg) were
randomly assigned to either: (1) DASH diet alone (DASH-A); (2) DASH diet with aerobic exercise
and caloric restriction (DASH-WM); or usual diet controls (UC). Body composition, fitness, insulin
sensitivity, and fasting lipids were measured before and following 4 months of treatment. Insulin
sensitivity was estimated based on glucose and insulin levels in the fasting state and after an oral
glucose load. Participants in the DASH-WM condition lost weight (−8.7 [95% CI = −2.0, −9.7] kg,),
and exhibited a significant increase in aerobic capacity, while the DASH-A and UC participants
maintained their weight (−0.3 [95% CI = −1.2, 0.5] kg and +0.9 [95% CI = 0.0, 1.7] kg, respectively)
and had no improvement in exercise capacity. DASH-WM demonstrated lower glucose levels
following the oral glucose load, improved insulin sensitivity, and lower total cholesterol and
triglycerides compared to both DASH-A and UC, and lower fasting glucose and low-density
lipoprotein cholesterol compared to UC; DASH-A participants generally did not differ from UC in
these measures. Combining the DASH diet with exercise and weight loss resulted in significant
improvements in insulin sensitivity and lipids. Despite clinically significant reductions in blood
pressure, the DASH diet alone, without caloric restriction or exercise, resulted in minimal
improvements in insulin sensitivity or lipids.
Keywords
Diet; Hypertension; Lipids; Insulin Resistance; Exercise
Corresponding Author: James A. Blumenthal, Ph.D., Professor of Medical Psychology, Duke University Medical Center Box 3119,
Durham, NC 27710, Telephone: 919-684-3828, Fax: 919-684-8629, Blume003@mc.duke.edu.
Clinical Trial Registration: clinicaltrials.gov Identifier: NCT00571844
Disclosures
None reported.
NIH Public Access
Author Manuscript
Hypertension. Author manuscript; available in PMC 2011 May 1.
Published in final edited form as:
Hypertension. 2010 May ; 55(5): 1199–1205. doi:10.1161/HYPERTENSIONAHA.109.149153.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Introduction
High blood pressure (HBP) affects more than 70 million Americans and is among the most
common reasons for outpatient visits to physicians’ offices1. Although HBP can be lowered
pharmacologically2, 3 anti-hypertensive medications may be costly, oftentimes must be used
in combination to achieve adequate blood pressure (BP) control, and can be associated with
side effects that impair quality of life and reduce adherence2, 4. Moreover, metabolic
abnormalities associated with HBP, such as insulin resistance and hyperlipidemia, may persist
or may be exacerbated by some medications5. Consequently, there is great deal of interest in
the use of non-pharmacologic interventions in the prevention and management of HBP.
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and
Treatment of High Blood Pressure (JNC 7)6 recommends that lifestyle modifications such as
weight loss and regular aerobic exercise be the initial treatment strategy for lowering HBP,
and specifically recommends the Dietary Approaches to Stop Hypertension (DASH) diet-- a
diet rich in fiber, fruits, vegetables and low-fat dairy products, and low in fat. This diet was
established as efficacious in reducing BP in a series of 4 to 8 week “feeding” trials, in which
HBP patients were provided DASH meals in a controlled environment7, 8. A subsequent
randomized trial to examine the efficacy of the DASH diet in an outpatient setting, the
PREMIER study9 demonstrated that the DASH diet could be successfully implemented in free-
living persons. Both “established” JNC 610 recommendations and the JNC 6 recommendations
plus the DASH diet (i.e., JNC 7 recommendations6) were associated with significant BP
reductions compared to advice only controls. In an ancillary study, Ard et al.11 reported results
from a subsample of 52 PREMIER participants who received an oral glucose tolerance test
(OGTT) at baseline and following 6-months of treatment. Those who received the
“established” intervention with or without the DASH diet showed greater improvements in
fasting insulin and glucose compared to controls, but only the “established plus DASH”
intervention achieved greater improvements in insulin sensitivity. However, because
participants in the “established plus DASH” treatment tended to lose more weight and reduce
their waist circumference compared to participants in both the advice only control condition
and the JNC 6 “established” intervention condition, the incremental benefit of the DASH diet
to lifestyle modifications of weight loss, exercise, and sodium restriction could not be
determined.
In an effort to examine the independent and combined effects of the DASH diet and weight
loss plus exercise on BP and biomarkers of risk, the ENCORE study examined 4 months of
treatment with the DASH diet alone, without exercise or weight loss (DASH-A), or the DASH
diet combined with a behavioral weight management program including caloric restriction and
aerobic exercise (DASH-WM), in 144 men and women with HBP12. Results showed that both
DASH-A and DASH-WM were associated with larger BP reductions compared to a usual diet
control (UC) group, although the DASH-WM condition achieved larger BP reductions and
greater improvements in such cardiovascular biomarkers as pulse wave velocity, baroreflex
sensitivity, and left ventricular mass. The present study reports the findings from the ENCORE
study on the secondary outcomes of insulin sensitivity and lipids.
Methods
Participants
As described in our primary paper12, the ENCORE trial enrolled 144 healthy, but overweight
adults with HBP (Figure 1). Persons were eligible if they were not taking anti-hypertensive
medication and had a mean systolic blood pressure (SBP) 130–159 or diastolic blood pressure
(DBP) 85–99 mm Hg averaged over four separate BP screening visits. Potential participants
were asked to refrain from smoking or ingesting caffeine for at least 30-min prior to their
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appointment time. BP measurements were standardized for cuff size, position, environment,
and time of day. Other inclusion criteria included age 35 years or older, body mass index (BMI)
of 25–40 kg/m2, sedentary (i.e., not engaged in regular exercise), and no other medical
comorbidities that would preclude safe participation in the trial, including diabetes requiring
insulin or oral hypoglycemic agents. Clinic BPs were determined according to JNC 7 guidelines
using a standard mercury sphygmomanometer and stethoscope.
Trial Overview
The ENCORE study was approved by the Institutional Review Board at Duke University
Medical Center and written informed consent was obtained from all participants. Following
completion of a series of baseline assessments (see below), participants were randomized to
the DASH diet alone (DASH-A) or the DASH diet combined with a behavioral weight
management program (DASH-WM), or to usual diet controls (UC). At the conclusion of the
4-month treatment period, assessments were repeated.
Assessments of Body Composition, Dietary Content, and Aerobic Fitness
Body weight was measured by a standard balance scale with participants dressed in light
clothing without shoes. Body composition and fat distribution were assessed by dual energy
absorptiometry (DEXA). This procedure provides measurements of fat mass, lean body mass,
and percent body fat for both the whole body and designated anatomical subregions13. An
independent assessment of dietary and nutritional content was obtained by two separate self-
report measures of diet: a retrospective food frequency questionnaire (FFQ)14, requiring
participants to recall typical consumption over a 4-week period, and a 4-day food diary. The
FFQ was analyzed by NutritionQuest (Berkeley, CA), while the diary data were analyzed using
Food Processor SQL Edition software (version 10.3, ESHA Research, Salem, OR)15. Fitness
was measured with a maximal graded exercise treadmill test in which workloads were increased
at a rate of one metabolic equivalent per minute16. Expired air was collected by mouthpiece
for quantification of minute ventilation, oxygen consumption, and carbon dioxide production
with a Parvo Medics True One measurement system (Model 2400; Parvo Medics, Sandy, Utah).
Assessments of Insulin Sensitivity and Lipids
Measures of glucose tolerance and insulin sensitivity were based on results of an oral glucose
tolerance test (OGTT) using an oral glucose load of 75g, with measurement of plasma glucose
(by Beckman auto-analyzer) at 0, 30, 60, 90, and 120 minutes and insulin (by double-antibody
radioimmunoassay) at 0 and 120 minutes. Insulin sensitivity was assessed using the
quantitative insulin sensitivity check index (QUICKI), as described by Katz, et al.17 and using
a method based on dynamic glucose and insulin levels -- the Insulin Sensitivity Index
(ISI0, 120), as described by Gutt, et al18. Both of these surrogate measures of insulin sensitivity
provide estimates of insulin sensitivity that correlate closely with glucose clamp measurements
and are predictive of the onset of type 2 diabetes19, 20.
Lipid profiles, including total cholesterol, high-density lipoprotein (HDL)- and low-density
lipoprotein (LDL)-cholesterol, very-low-density lipoprotein (VLDL)-cholesterol, and
triglycerides were obtained from fasting blood samples drawn between 0800 and 0900 hrs;
assays were measured enzymatically (Labcorp Inc, Burlington, NC).
Randomization
Upon completion of the baseline assessments, patients were randomized in blocks of 2–5
participants. Participants were provided their group assignments in sealed envelopes; staff
performing assessments was unaware of participants’ treatment group assignments.
Assignments were stratified by baseline clinic BP, BMI, and age.
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Interventions
Immediately following randomization, participants received 2-week controlled feeding on the
Duke Clinical Research Unit, in which they ate the assigned dietary patterns (controlled usual
diet, DASH diet or a reduced calorie DASH diet). Participants ate their evening meal on the
unit, and took home their breakfast, lunch and snack for the following day. The controlled
feeding period was modeled after the original DASH feeding studies7, 8. Participants in the
DASH-A and UC conditions consumed study meals isocalorically for weight maintenance,
whereas the caloric level in the DASH-WM arm was set at a 500 calories per day deficit to
allow weight loss of about 0.5–1.0 pound a week.
After the first 2 weeks of controlled feeding, participants were instructed to maintain the DASH
diet either with (DASH-WM) or without weight loss (DASH-A). Participants in the DASH-A
condition met weekly with a nutritionist and modified the content of their diet to meet DASH
guidelines but did not exercise or attempt to lose weight.
Participants in the DASH-WM condition received the same instruction in the DASH diet from
the same nutritionist as in the DASH-A group, but also met with a clinical health psychologist
who provided a structured, cognitive behavioral weight loss intervention that employed
cognitive behavioral strategies21 and appetite awareness training22; the DASH
recommendations provided participants with guidance regarding what to eat, while weight
management (WM) was designed to help individuals learn when, how, and how much to eat.
Participants also engaged in supervised exercise 3-times per week for 30 minutes at a level of
70–85% of their initial heart rate reserve determined during their baseline treadmill test.
Participants in the UC condition were asked to maintain their usual dietary and exercise habits
for 4 months until they were re-evaluated. Weight and BP were monitored biweekly.
Statistical Analysis
Treatment effects were evaluated using the general linear model in the SAS 9.1 software (SAS
Institute, Cary, NC), with separate models for each outcome. Each model included treatment
condition as a three-level factor, and the corresponding pre-treatment value of the outcome,
age, gender, and ethnicity (Caucasian vs. non Caucasian) as adjustment covariables. We
compared post-treatment group means using pairwise treatment group comparisons that were
adjusted using Tukey’s Honestly Significant Difference procedure. Data for all outcomes were
analyzed following the intent-to-treat principle, with missing data managed using the multiple
imputation method available in SAS PROC MI. For a given outcome, we estimated that we
would have about 80% power to detect a 0.5 standard deviation difference between the active
treatments and UC, and a 0.6 standard deviation difference between DASH-A and DASH-WM.
Results
Participant flow
As described previously12, 3129 participants initially inquired about the study, 447 met our
initial inclusion criteria, and 144 participants were randomized to the DASH-WM (N=49);
DASH-A (N=46); or UC (N=49). Post-treatment glucose and lipid data were available for 46
participants in DASH-WM, 44 in DASH-A, and 48 in UC. For body composition variables,
post-treatment data were available for 46 participants in DASH-WM, 46 in DASH-A, and 47
in UC.
Participant characteristics
Table 1 displays the demographic and medical characteristics of the sample across the three
treatment groups at baseline. On average, participants were 52 years old; 39% were African
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American and 67% were women. The mean clinic BP was 138/86 mm Hg. The majority of
participants were college-educated and relatively affluent. The groups were generally
comparable across the background variables.
Adherence to protocol
Attendance to the exercise and diet classes was excellent. DASH-WM participants attended
90% (median = 38) of scheduled exercise sessions and spent most time (median = 94%) at or
above their target heart rate training range. DASH dietary class attendance also was excellent,
with the median number of sessions attended 12 (92%) in both intervention groups. As reported
previously12, compared to DASH-A and UC, participants in DASH-WM on average consumed
significantly fewer total calories (1648 [95% CI = 1521–1774] kcal, 1962 [95% CI = 1833–
2090] kcal, 2095 [95% CI = 1961–2228] kcal for DASH-WM, DASH-A, and UC respectively),
and both DASH conditions consumed more calories from protein (19.5%, 19.4%, 16.7% for
DASH-WM, DASH-A, and UC respectively), less saturated fat (26.3%, 27.8%, 36.8% for
DASH-WM, DASH-A, and UC respectively), and more fiber (25g, 26g, 16 g for DASH-WM,
DASH-A, and UC respectively) compared to those in UC (P’s < .001).
Changes in body weight and body composition
Adjusting for baseline weight, age, gender, and ethnicity, the mean post-treatment weight for
the DASH-WM group was significantly lower (84.5 kg) compared to DASH-A (92.9 kg; p < .
001) and to UC (94.1 kg; p < .001). The weight change was −8.7 kg in DASH-WM, −0.3 kg
in DASH-A, and +0.9 kg in UC.
Following treatment, the DASH-WM group showed lower percent body fat and trunk fat
compared to DASH-A and UC (Table 2). DASH-WM also had lower lean body mass compared
to the other groups. DASH-A did not differ significantly from UC on any body composition
measure.
Changes in aerobic fitness
Adjusting for pretreatment levels, age, gender, and ethnicity, the mean post-treatment peak
maximal oxygen consumption (VO2) was higher in DASH-WM (29 ml/kg/min) compared to
DASH-A (23 ml/kg/min, p < .001) and UC (22 ml/kg/min) (p < .001). Participants in the
DASH-WM group showed a 19% increase in peak VO2, compared to small, and non-
significant, decreases in the DASH-A (−1.2%) and UC (−3.2%).
Glucose Tolerance and Insulin Sensitivity
Results of the OGTT revealed that participants in the DASH-WM condition achieved greater
improvements in glucose response compared to DASH-A and UC (Figure 2). Compared to
UC, participants in the DASH-WM group showed lower fasting glucose levels (Table 3).
DASH-WM also exhibited lower glucose AUC and greater insulin sensitivity, as measured by
both QUICKI and ISI0, 120 compared to DASH-A or UC. DASH-A did not differ from UC on
any measure of glucose metabolism or insulin sensitivity.
We also noted that 24% (N = 34) of participants were considered overweight (BMI = 25–29.9),
while 76% (N = 110) were considered obese (BMI >30) at baseline. The treatment group by
BMI interaction was not significant, however, for glucose AUC (p = .385), QUICKI (p = .528),
or ISI0, 120 (p = .142), suggesting that pre-treatment body weight did not moderate the effects
of treatment on glucose metabolism or insulin sensitivity.
In a post hoc analysis, participants were classified as diabetic (>199 mg/dl), pre-diabetic (141–
199 mg/dl), or normal (<140 mg/dl) based upon their glucose levels at 2 hrs during the OGTT.
Overall, 72% (N=13) of the 18 participants in DASH-WM who were either prediabetic or
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diabetic at study entry improved by at least one category over the course of the trial, compared
to 54% (7/13) in DASH-A and 42% (8/19) in UC. Among participants who were either not
diabetic or pre-diabetic upon study entry, diabetic classification worsened in only 2% (1/44)
of participants in DASH-WM, compared to 16% (7/43) in DASH-A and 11% (5/46) in UC.
Serum Lipids
Participants in the DASH-WM group obtained significantly lower total cholesterol and
triglyceride levels compared to DASH-A and UC participants and lower LDL-cholesterol
levels compared to UC, but not DASH-A (Table 4). Participants in DASH-A had marginally
lower HDL-cholesterol levels than UC, but otherwise participants in DASH-A were not
different from UC participants on any other lipid measure.
Discussion
Our findings demonstrate that adherence to the DASH diet alone, although sufficient to modify
BP values12, resulted in significant improvements in metabolic indices of cardiovascular risk
only when accompanied by aerobic exercise and weight loss. In the DASH-WM group,
participants lost an average of 19 pounds over 4 months and increased their aerobic capacity
by 19%. While both the DASH-A and DASH-WM groups achieved clinically meaningful
reductions in BP and improvements in other cardiovascular biomarkers of risk, as described
in our earlier publication12, only DASH-WM participants demonstrated significant
improvements in glucose tolerance and insulin sensitivity.
Although the DASH diet has been shown to reduce BP in controlled “feeding” studies7, 8 and
in studies of free living individuals9, 12 the present study found that ENCORE participants who
adhered to the DASH diet but did not exercise or lose weight achieved minimal improvements
in glucose metabolism or insulin sensitivity, and also in lipids, relative to controls. Our findings
contrast with results from the PREMIER substudy11, in which addition of the DASH diet to
an established intervention of weight loss, reduced sodium intake, increased physical activity,
and moderation of alcohol intake resulted in a significant improvement in insulin sensitivity
relative to controls. However, because there was no difference in insulin sensitivity between
groups randomized to the established intervention with or without the DASH diet, and there
was a trend toward greater weight loss in the DASH group, the added value of the DASH diet
is uncertain. The present ENCORE study findings indicate that despite DASH-related
reductions in BP12, the DASH diet by itself produced minimal improvements in insulin
sensitivity.
Our study was designed to evaluate only the DASH diet, and it is possible, even likely, that
other diets, either alone or combined with exercise, could be beneficial. Many studies have
examined the impact of various diets on weight loss23–26. Sacks et al.23, for example,
randomized overweight adults to one of four diets in which the targeted percentages of energy
derived from fat, protein and carbohydrates varied. After 2 years, groups achieved similar
benefits in weight loss and lipid-related risk factors and fasting insulin levels. It was concluded
that reduced calorie diets result in significant weight loss regardless of the macronutrient
content. Foster and colleagues25 reported that a low carbohydrate, high protein and high fat
(Atkins) diet was associated with greater weight loss after 6 months compared to a conventional
low fat, low calorie, high carbohydrate diet, but that the differences were not significant after
12 months. With respect to body composition, the present findings confirm the results of
previous findings suggesting that a low fat, weight loss diet (50% carbohydrate, 30% fat, 20%
protein) results in reduced lean body mass. However, very low carbohydrate diets have been
found to result in even greater reductions in weight and lean body mass compared to low fat
diets27–29. Lipid changes were generally similar over time, and both diets were associated with
lower DBP and insulin response to an oral glucose load.
Blumenthal et al. Page 6
Hypertension. Author manuscript; available in PMC 2011 May 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
While weight loss is associated with improved lipids, particularly LDL-cholesterol30, and
increased insulin sensitivity31–33, diet composition also may affect lipids and glucose
metabolism independent of weight loss. For example, with a 4-week, isocaloric weight
maintenance diet, both the Ornish diet and South Beach diet have been shown to favorably
reduce lipids, while high fat diets may be associated with increased LDL and total cholesterol
levels34. However, the number of calories consumed appears to be more important relative to
the content of the calories with regard to the development of diabetes35.
Exercise also was a key component of the DASH-WM intervention, but its effects on insulin
sensitivity could not be determined independent from weight loss. Although exercise is widely
considered to be important for successful weight loss, studies of the effects of exercise in the
absence of weight loss on glucose, insulin sensitivity and lipids have produced mixed results.
Exercise has been shown to improve insulin sensitivity, either due to chronic effects of exercise
training or to the residual effects of acute exercise. Studies of both healthy adults and patients
with type 2 diabetes have demonstrated that improved insulin sensitivity is maintained up to
16 hr after a single bout of exercise36, 37 but may be diminished 60 hours after the final exercise
training session38, 39. Some studies have demonstrated that exercise training is associated with
reduced glucose levels and improved glycemic control40–44, while others have not45–50.
Because studies that have shown improvements in glucose control after exercise training have
not established that these effects are due to exercise independent of weight loss51, the extent
to which the exercise component of the DASH-WM condition contributed to the metabolic
improvements observed in the ENCORE study is not known. The effects of exercise training
on lipids also have provided mixed results52 although recent evidence suggests that high levels
of exercise without weight loss may be required to achieve improvements in lipid and
lipoprotein variables53.
Finally, it should be noted that some studies also have suggested that obesity may moderate
the effects of exercise training on insulin sensitivity. Poirier et al.48, for example, reported no
improvement in insulin sensitivity in obese type 2 diabetic patients after 12 weeks of aerobic
training, although insulin sensitivity was improved in nonobese type 2 diabetic subgroups. Our
data, in overweight but non-diabetic patients revealed no evidence that obesity moderated the
effects of treatment. Therefore, our findings suggest that the improvements in insulin sensitivity
observed in the DASH-WM intervention are generalizable to both obese and non-obese
populations.
Perspectives
In summary, the results of the ENCORE study indicate that while the DASH diet alone can
reduce BP in overweight, sedentary adults with HBP, there was little evidence that the DASH
diet improved insulin sensitivity or lipids without the addition of exercise and weight reduction.
It would appear that caloric consumption rather than nutrient composition is most salient for
improved metabolic function.
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Figure 1.
Participant flow in the ENCORE clinical trial. OGTT indicates oral glucose tolerance test; ITT
refers to intent-to-treat.
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Figure 2.
Post-treatment glucose response during oral glucose tolerance test. Values are adjusted for
pretreatment glucose levels, gender, age, and ethnicity. Error bars represent 95% confidence
limits.
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Table 1
Background characteristics of the sample
Demographics DASH-WM DASH-A UC All
N=49 N = 46 N = 49 N = 144
Age (years) 52.3 (10) 51.8 (10) 51.8 (9) 52.0 (10)
Gender: Female 69% (34) 63% (29) 69% (34) 67% (97)
Ethnicity
 Caucasian 69% (34) 50% (23) 59% (29) 60% (86)
 African American 31% (15) 48% (22) 39% (19) 39% (56)
 Asian 0% (0) 2% (1) 2% (1) 1% (2)
Level of Education
 High School 31% (15) 30% (14) 42% (20) 34% (49)
 Some College 8% (4) 9% (4) 14% (7) 11% (15)
 Completed College 29% (14) 30% (14) 18% (9) 22% (32)
 Post-Graduate School 20% (10) 28% (13) 20% (10) 24% (34)
 Other 12% (6) 13% (6) 2% (1) 9% (13)
Weight (kg) 93.9 (14) 93.0 (14) 92.6 (15) 93.1 (14.1)
BMI (kg/m2) 33.5 (4.4) 32.8 (3.4) 33.0 (3.9) 33.1 (3.9)
Values are mean (standard deviation) for continuous variables and group percent (n) for categories.
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